This work suggests that identifying and obtaining consensus as to the cause of mortality reductions seen during PSA mass utilization is of the utmost importance, as we strive to improve outcomes overall while reducing historical disparities in prostate cancer outcomes. This evidence concerns the gene KLK3 and prostate carcinoma.